ArticleACS nano2026
Engineered Coiled-Coils Convert Cholera Toxin B-Pentamers into Programmable Membrane Fusogens.
Article in ACS nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Membrane fusion is central to biological function and bioengineering, yet few design rules exist that enable proteins to be programmed to drive fusion at defined membrane interfaces. Here, we show that cholera toxin B-subunit (CTB), a naturally occurring glycolipid-binding pentamer, can be re-engineered into a programmable membrane fusogen by assembling two CTB units through rationally designed coiled-coil linkers attached to the CTA2 peptide that threads through the CTB pentamer. Using discrete parallel and antiparallel coiled-coil architectures, we generated CTB dimers with defined orientations and examined their ability to drive fusion of giant unilamellar vesicles containing the CTB ligand ganglioside GM1. Fusion efficiency was evaluated using a fluorescence resonance energy transfer (FRET)-based lipid mixing assay, while flow cytometry, confocal microscopy, and quartz crystal microbalance with dissipation monitoring (QCM-D) provided mechanistic insights. Both parallel and antiparallel CTB dimers induced cross-linking and full fusion; strikingly, fusogenic efficiency was governed primarily by the length of the CTA2 linker rather than coiled-coil orientation. These findings establish a generalizable strategy for engineering lectin-based fusogens with tunable activity, defining linker geometry as a key design parameter and advancing the development of programmable membrane fusion platforms for drug delivery and synthetic cell systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.